Regulatory FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program FDAThe U.S.RegulatoryGene TherapyRead full story pharminent April 23, 2026 (Last updated: April 24, 2026) FDA The U.S. RegulatoryGene TherapyRead full story Post navigation Previous: CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug CoverageNext: FDA approves Regeneron’s hearing loss gene therapy Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026